Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CDC Advisory Committee Recommends GSK’s Cervarix
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended that GlaxoSmithKline’s (GSK) Cervarix be given to girls and young women
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended that GlaxoSmithKline’s (GSK) Cervarix be given to girls and young women
Kaiser Permanente is initiating a clinical trial to help obese women control their weight during pregnancy. The ‘Healthy Moms’ study, funded by a $2.2m grant from the National
VeriChip has entered into a strategic partnership with the Diabetes Research Institute (DRI) to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip,
Peregrine Pharmaceuticals has reported positive results from its phase II trial evaluating bavituximab in combination with docetaxel, in patients with advanced breast cancer. Bavituximab is a monoclonal antibody
Endocyte has presented data from a phase 2a clinical trial for EC145, currently in development as a potential treatment for advanced ovarian cancer. Results were presented at the
Entest BioMedical has signed a letter of intent to acquire Therinject. Therinject is involved with Cancer Research, marker testing/development and ‘bead’ formation used in vaccine development. The company
MeadWestvaco (MWV) and Persistent Systems have announced that MWV has sold its Paxonix business to software development services company, Persistent Systems. Paxonix provides web-based branding and packaging process
Actelion has announced its financial results for the first nine months of 2009, with total net revenues of CHF1,302.5m and operating expenses of CHF939.3m. The company reported an
Almirall has completed a short-term phase II study comparing aclidinium twice daily (BID) vs tiotropium and placebo and has also completed the enrollment of a larger phase III
Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) have presented results from BLISS-52, the first of two pivotal phase 3 trials of belimumab in seropositive patients with systemic lupus